Notable Facts
→CEO of Liquidia Corporation since January 2022
→Led United Therapeutics as President & Co-CEO from 2015-2016 after 18-year tenure starting in 1998
→Helped lead United Therapeutics IPO and secured FDA approval for 6 rare disease products
→Drove United Therapeutics to >20% CAGR, $1.5B annual revenue run rate, and $8B peak market cap
→Vice-Chairman and Co-Founder of Kriya Therapeutics (gene therapy company)
→Served on multiple biotech company boards: Axsome Therapeutics (current), Dova, Sangamo, Axovant, Albireo
→PhD in Pharmacology from UNC School of Medicine; BS Chemistry from Duke University
→Authored 60+ peer-reviewed publications on pulmonary hypertension
→Currently leads Liquidia's successful commercial launch of YUTREPIA for pulmonary arterial hypertension
→Net worth estimated at $111M+ with significant equity stakes in multiple biotech companies